comparemela.com

Page 40 - Company Forward News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-News: SFC Energy AG publishes preliminary Group figures for 2022 Record growth again and increase in earnings

SFC Energy AG publishes Half-Year Report 2022 – Continuation of dynamic growth and confirmation of the forecast for 2022

DGAP-News: SFC Energy AG publishes Half-Year Report 2022 Continuation of dynamic growth and confirmation of the forecast for 2022

Mimi s Rock Reports Q2 2022 Results

Innovent and Lilly Jointly Announce the Approval of TYVYT (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma

SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Eli Lilly and Company ("Lilly", NYSE: LLY) today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for TYVYT (sintilimab injection) in combination with cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC). This is the fifth NMPA-approved indication of TYVYT. In China, TYVYT was approved for: the treatment of relapsed or refractory classical Hodgkin's lymphoma in Dece

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.